CD4 and colitis: In contrast to the direct in vitro suppression of IL-10 expression by tofacitinib, however, the number of IL-10+ CD4+ T cells in colitis mice on day 90 could not only be reverted by the late administration of tofacitinib but also sometimes even exceeded the levels observed in control mice (Figure 6C).